Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Vlado Perkovic(New South Wales Department of Health), Bruce Neal(UNSW Sydney), Dick de Zeeuw(University Medical Center Groningen), Hsiaowei Deng(Janssen (United States)), Michele A. Weidner‐Wells(Janssen (United States)), Greg Fulcher(The George Institute for Global Health), Ngozi Erondu(The George Institute for Global Health), Terrance D. Barrett(Janssen (United States)), David R. Matthews(Manchester College), Wayne Shaw(The George Institute for Global Health), Kenneth W. Mahaffey(Cardiovascular Institute of the South)
The Lancet Diabetes & Endocrinology
June 21, 2018
10.1016/s2213-8587(18)30141-4
Cited by 642

Related Papers

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k